Stock Scorecard

Stock Summary for Regeneron Pharmaceuticals Inc (REGN) - $743.35 as of 11/20/2024 8:38:26 PM EST

Total Score

15 out of 30

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for REGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for REGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for REGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for REGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for REGN (69 out of 90)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 8

Latest News for for REGN

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 11/19/2024 5:15:00 PM
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 11/18/2024 1:15:00 PM
EQS-News: Formycon receives positive CHMP opinion for FYB203 ( aflibercept ) , a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 11/18/2024 5:30:00 AM
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 11/15/2024 3:35:00 PM
FDA To Review Once Rejected Regeneron/Sanofi's Blockbuster Dupixent For Type Of Inflammatory Skin Disease - Regeneron Pharmaceuticals ( NASDAQ:REGN ) , Sanofi ( NASDAQ:SNY ) 11/15/2024 1:44:00 PM
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria 11/15/2024 6:00:00 AM
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 11/15/2024 6:00:00 AM
Dupixent® ( dupilumab ) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria ( CSU ) 11/15/2024 5:59:00 AM
2 Top Growth Stocks to Buy on the Dip 11/14/2024 12:00:00 PM
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Regeneron Pharmaceuticals ( NASDAQ:REGN ) , Sanofi ( NASDAQ:SNY ) 11/13/2024 4:06:00 PM

Financial Details for REGN

Company Overview
Ticker REGN
Company Name Regeneron Pharmaceuticals Inc
Country USA
Description Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 1/31/2025

Stock Price History
Last Day Price 743.35
Price 4 Years Ago 483.11
Last Day Price Updated 11/20/2024 8:38:26 PM EST
Last Day Volume 654,394
Average Daily Volume 795,035
52-Week High 1,211.20
52-Week Low 750.20
Last Price to 52 Week Low 0.91%

Valuation Measures
Trailing PE 18.73
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 18.50
Free Cash Flow Ratio 8.20
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 5.28
Total Cash Per Share 90.65
Book Value Per Share Most Recent Quarter 272.04
Price to Book Ratio 2.84
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 6.01
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 8

Share Statistics
Total Shares Outstanding 108,072,000
Market Capitalization 80,335,321,200
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.78%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 29.80%
Annual Earnings Growth -8.87%
Reported EPS 12 Trailing Months 40.41
Reported EPS Past Year 33.57
Reported EPS Prior Year 43.78
Net Income Twelve Trailing Months 4,654,500,000
Net Income Past Year 3,953,600,000
Net Income Prior Year 4,338,400,000
Quarterly Revenue Growth YOY 10.60%
5-Year Revenue Growth 14.31%
Operating Margin Twelve Trailing Months 0.33

Balance Sheet
Total Cash Most Recent Quarter 9,796,500,000
Total Cash Past Year 10,844,800,000
Total Cash Prior Year 7,742,300,000
Net Cash Position Most Recent Quarter 7,812,500,000
Net Cash Position Past Year 8,861,900,000
Long Term Debt Past Year 1,982,900,000
Long Term Debt Prior Year 1,981,400,000
Total Debt Most Recent Quarter 1,984,000,000
Equity to Debt Ratio Past Year 0.93
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 25,973,100,000
Total Stockholder Equity Prior Year 22,664,000,000
Total Stockholder Equity Most Recent Quarter 29,325,900,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 3,439,700,000
Free Cash Flow Per Share Twelve Trailing Months 31.83
Free Cash Flow Past Year 3,875,400,000
Free Cash Flow Prior Year 4,424,800,000

Options
Put/Call Ratio 0.44
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -56.53
MACD Signal -54.76
20-Day Bollinger Lower Band 810.95
20-Day Bollinger Middle Band 1,046.62
20-Day Bollinger Upper Band 1,282.28
Beta 0.14
RSI 17.87
50-Day SMA 987.87
150-Day SMA 806.97
200-Day SMA 745.39

System
Modified 11/19/2024 11:20:32 AM EST